---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020063"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:43:10.155040+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Beam Q1 net loss $96.5M ($1.33/sh); BEACON trial advancing, BEAM-201 on track

## Summary
- Net loss $96.5M ($1.33/sh) vs $69.2M ($1.01/sh) YoY; R&D spend up to $99.6M.
- Cash, equivalents and securities $1.1B; runway expected at least into 2025.
- BEACON trial sentinel cohort: first patient withdrawn (non-medical), 2 enrolled; full cohort expected in 2023.
- BEAM-201 Phase 1/2 for T-ALL/T-LL on track to dose first patient by mid-2023.
- Gopi Shanker appointed CSO; regulatory filings for BEAM-301 (late 2023/early 2024) and BEAM-302 (early 2024).

## SEC filing metadata
- accession: 0000950170-23-020063
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000095017023020063/0000950170-23-020063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000095017023020063/beam-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020063
- JSON: https://secwatch.observer/filing/0000950170-23-020063.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020063.txt

## Key facts
- Earnings Releases
  Beam Therapeutics Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share, EPS $1.33 per share.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share
  - EPS: $1.33 per share
  - Result: reported results
  source text: Net loss was $96.5 million for the first quarter of 2023, or $1.33 per share, compared to $69.2 million for the first quarter of 2022, or $1.01 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000095017023020063/0000950170-23-020063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.